APA (7th ed.) Citation

Mueller, M., Himmler, S., Basic, E., & Hradetzky, E. (2017). PCV2 - Long-Term Health Benefits of Treating Non-Valvular Atrial Fibrillation with Apixaban Versus Vitamin K Antagonists In Germany: A Population-Based Modelling Study. Value in Health, 20(9), A600. https://doi.org/10.1016/j.jval.2017.08.1147

Chicago Style (17th ed.) Citation

Mueller, M., S. Himmler, E. Basic, and E. Hradetzky. "PCV2 - Long-Term Health Benefits of Treating Non-Valvular Atrial Fibrillation with Apixaban Versus Vitamin K Antagonists In Germany: A Population-Based Modelling Study." Value in Health 20, no. 9 (2017): A600. https://doi.org/10.1016/j.jval.2017.08.1147.

MLA (9th ed.) Citation

Mueller, M., et al. "PCV2 - Long-Term Health Benefits of Treating Non-Valvular Atrial Fibrillation with Apixaban Versus Vitamin K Antagonists In Germany: A Population-Based Modelling Study." Value in Health, vol. 20, no. 9, 2017, p. A600, https://doi.org/10.1016/j.jval.2017.08.1147.